Effects of anti-somatostatin agents on glucose metabolism

Diabetes and Metabolism

Volumn 43, Issue 5, 2017, Pages 411-415

  Verges B ^a,b  

^a HÔPITAL DU BOCAGE   (France)

^b boulevard Jeanne d'Arc   (France)

Author keywords

Acromegaly; Cushing; Diabetes; Hyperglycaemia; Pasireotide; Somatostatin

Indexed keywords

ANGIOPEPTIN; GLUCOSE; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN;

ACROMEGALY; CUSHING DISEASE; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; GLUCOSE METABOLISM; HUMAN; NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY; REVIEW; ANALOGS AND DERIVATIVES; CARBOHYDRATE METABOLISM; CHEMICALLY INDUCED; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; METABOLISM;

ACROMEGALY; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; GLUCOSE; HUMANS; HYPERGLYCEMIA; PITUITARY ACTH HYPERSECRETION; SOMATOSTATIN;

EID: 85020111200     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2017.05.003     Document Type: Review

References (29)

1. Feelders, R.A., Hofland, L.J., van Aken, M.O., Neggers, S.J., Lamberts, S.W.J., de Herder, W.W., et al. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69 (2009), 2207–2226.
2. Yang, L.P.H., Keating, G.M., Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 70 (2010), 1745–1769.
3. McKeage, K., Pasireotide in acromegaly: a review. Drugs 75 (2015), 1039–1048.
4. Ceccato, F., Scaroni, C., Boscaro, M., Clinical use of pasireotide for Cushing's disease in adults. Ther Clin Risk Manag 11 (2015), 425–434.
5. Lee, P.E., Meneilly, G.S., The effect of octreotide on glucose and insulin levels in a patient with type 2 diabetes on glibenclamide. Diabetes Metab 25 (1999), 347–349.
6. Steffin, B., Gutt, B., Bidlingmaier, M., Dieterle, C., Oltmann, F., Schopohl, J., Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155 (2006), 73–78.
7. Lunetta, M., Di Mauro, M., Le Moli, R., Nicoletti, F., Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients. Diabetes Res Clin Pract 38 (1997), 81–89.
8. Di Mauro, M., Papalia, G., Le Moli, R., Nativo, B., Nicoletti, F., Lunetta, M., Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function. Diabetes Res Clin Pract 51 (2001), 45–50.
9. Boyle, P.J., Justice, K., Krentz, A.J., Nagy, R.J., Schade, D.S., Octreotide reverses hyperinsulinemia and prevents hypoglycaemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 76 (1993), 752–756.
10. Valassi, E., Santos, A., Yaneva, M., Tóth, M., Strasburger, C.J., Chanson, P., et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165 (2011), 383–392.
11. Boscaro, M., Bertherat, J., Findling, J., Fleseriu, M., Atkinson, A.B., Petersenn, S., et al. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, phase II study. Pituitary 17 (2014), 320–326.
12. Colao, A., Petersenn, S., Newell-Price, J., Findling, J.W., Gu, F., Maldonado, M., et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 366 (2012), 914–924.
13. Trementino, L., Cardinaletti, M., Concettoni, C., Marcelli, G., Boscaro, M., Arnaldi, G., Up to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary 18 (2015), 359–365.
14. MacKenzie Feder, J., Bourdeau, I., Vallette, S., Beauregard, H., Ste-Marie, L.-G., Lacroix, A., Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial. Pituitary 17 (2014), 519–529.
15. Dreval, A.V., Trigolosova, I.V., Misnikova, I.V., Kovalyova, Y.A., Tishenina, R.S., Barsukov, I.A., et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 3 (2014), 93–98.
16. Fieffe, S., Morange, I., Petrossians, P., Chanson, P., Rohmer, V., Cortet, C., et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164 (2011), 877–884.
17. Colao, A., Bronstein, M.D., Freda, P., Gu, F., Shen, C.-C., Gadelha, M., et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99 (2014), 791–799.
18. Gadelha, M.R., Bronstein, M.D., Brue, T., Coculescu, M., Fleseriu, M., Guitelman, M., et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 875–884.
19. Sheppard, M., Bronstein, M.D., Freda, P., Serri, O., De Marinis, L., Naves, L., et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18 (2015), 385–394.
20. Silverstein, J.M., Hyperglycaemia induced by pasireotide in patients with Cushing's disease or acromegaly. Pituitary 19 (2016), 536–543.
21. Cives, M., Kunz, P.L., Morse, B., Coppola, D., Schell, M.J., Campos, T., et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer 22 (2015), 1–9.
22. Kvols, L.K., Oberg, K.E., O'Dorisio, T.M., Mohideen, P., de Herder, W.W., Arnold, R., et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 19 (2012), 657–666.
23. Wolin, E.M., Jarzab, B., Eriksson, B., Walter, T., Toumpanakis, C., Morse, M.A., et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 9 (2015), 5075–5086.
24. Henry, R.R., Ciaraldi, T.P., Armstrong, D., Burke, P., Ligueros-Saylan, M., Mudaliar, S., Hyperglycaemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98 (2013), 3446–3453.
25. Singh, V., Brendel, M.D., Zacharias, S., Mergler, S., Jahr, H., Wiedenmann, B., et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 92 (2007), 673–680.
26. Golor, G., Hu, K., Ruffin, M., Buchelt, A., Bouillaud, E., Wang, Y., et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther 6 (2012), 71–79.
27. Breitschaft, A., Hu, K., Hermosillo Reséndiz, K., Darstein, C., Golor, G., Management of hyperglycaemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 103 (2014), 458–465.
28. Colao, A., De Block, C., Gaztambide, M.S., Kumar, S., Seufert, J., Casanueva, F.F., Managing hyperglycaemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary 17 (2014), 180–186.
29. Reznik, Y., Bertherat, J., Borson-Chazot, F., Brue, T., Chanson, P., Cortet-Rudelli, C., et al. Management of hyperglycaemia in Cushing's disease: experts’ proposals on the use of pasireotide. Diabetes Metab 39 (2013), 34–41.